- Prostatectomy and bladder surgery
- Conisation of the cervix
- Management of dental extraction in patients with coagulopathies
- Ulcerative colitis
- Gastrointestinal haemorrhage
General fibrinolysis as in prostatic and pancreatic cancer, after thoracic and other major surgery, in obstetrical complications such as abruptio placentae and post- partum haemorrhage, in leukaemia and liver diseases and in connection with thrombolytic therapy with streptokinase.
Hereditary angioneurotic oedema.
PHARMACOKINETICS: Tranexamic acid is rapidly absorbed from the gastrointestinal tract. Maximum serum levels are reached within 2-3 hours. After oral administration, about 40% of the dose is excreted in the urine during the first 24 hours. After intravenous administration 45% of the dose is excreted in the urine during the first day.
Dosage & Administration
PROSTATECTOMY: 5-10 ml by slow intravenous injection every eight hours (the first injection being given during the operation) for the first three days after surgery; thereafter 1-1.5 gm orally three to four times daily until macroscopic haematuria is no longer present.
MENORRHAGIA: 1-1.5 gm orally three to four times daily for three to four days.
EPISTAXIS: 1.5 gm orally three times daily for four to ten days. Tranexamic Acid injection may be applied topically to the nasal mucosa of patients suffering from epistaxis. This can be done by soaking a gauze strip in the solution, and then packing the nasal cavity.
HAEMATURIA: 1-1.5 gm orally 2-3 times daily until macroscopic haematuria is no longer present.
CONISATION OF THE CERVIX: 1.5 gm orally 3 times a day for 12 to 14 days post-operatively.
DENTAL SURGERY IN PATIENTS WITH COAGULOPATHIES: Immediately before surgery, 10 mg per kg body-weight should be given intravenously. After surgery, 25 mg per kg body-weight are given orally three to four times daily for six to eight days. Coagulation factor concentrate might be necessary to administrate.
GENERAL FIBRINOLYSIS: 1 gm by slow intravenous injection three to four times daily. With fibrinolysis in conjunction with diagnosed, increased intravascular coagulation i.e. defibrillation syndrome, an anticoagulant such as heparin may be given with caution.
HEREDITARY ANGIONEUROTIC OEDEMA: 1-1.5 gm orally two to three times daily as intermittent or continuous treatment depending on whether the patient has prodromal symptoms or not.
- Oral dose: 25 mg/kg 2 to 3 times daily for 7 to 10 days.
- Injection: 10 mg/kg 6 to 8 hours for 7 to 10 days
- Active thromboembolic disease, such as deep vein thrombosis, pulmonary embolism and cerebral thrombosis
- Subarachnoid haemorrhage
- Hypersensitivity to Tranexamic acid or any of the ingredients
Pregnancy & Lactation
Lactation: Tranexamic acid is excreted into breast milk, but it is not likely to influence the child at therapeutic doses.
Patients with disseminated intravascular coagulation (DIC), who require treatment with it must be under the strict supervision of a physician experienced in treating this disorder.
In the long-term treatment of patients, regular eye examination should be performed. If a colour vision disorder should occur during the course of treatment, the drug should be discontinued.
Treatment of overdose: If justified, initiate vomiting, then gastric lavage, charcoal therapy, and symptomatic treatment. Maintain adequate diuresis.
Use in Special Population
Intravenous: Adjust dose based on the serum-creatinine concentration:
- 120-250 micromol/l: 10 mg/kg bid daily;
- 250-500 micromoles/l: 10 mg/kg once daily;
- >500 micromol/l: 5 mg/kg once daily or 10 mg/kg once every 48 hr.
Oral: Adjust dose based on serum creatinine concentration:
- 120-250 micromol/l: 15 mg/kg bid daily;
- 250-500 micromol/l: 15 mg/kg once daily;
- >500 micromol/l: 7.5 mg/kg once daily or 15 mg/kg once every 48 hr.
Pediatric Use: The drug has had limited use in pediatric patients, principally in connection with tooth extraction. The limited data suggest that dosing instructions for adults can be used for pediatric patients needing Tranexamic acid therapy.
Geriatric Use: Clinical studies of Tranexamic acid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond different y from younger subjects. Other reported clinical experien e has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Drug Interaction Tranexamic Acid is known to interact with other drugs like Factor VIII. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required. Pharmaceutical Precaution Keep in a cool & dry place, protected from light. Keep out of the reach of children.